Clinical Trials Logo

High LDL-C clinical trials

View clinical trials related to High LDL-C.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01896037 Completed - Spinal Cord Injury Clinical Trials

Omega-3 Supplementation for Tetraplegics With Poor Cholesterol Levels

Start date: July 2013
Phase: Phase 4
Study type: Interventional

People with a spinal cord injury (SCI) characteristically have low levels of high-density lipoprotein-cholesterol (HDL-c; "good cholesterol") and high levels of low-density lipoprotein-cholesterol (LDL-c; "bad cholesterol"), and are at a higher risk of developing cardiovascular health problems, such as heart disease, heart attack and stroke, than the able-bodied population. A common way for able-bodied people to improve their lipid profile is through exercise; however, SCI people, especially tetraplegics, are often unable to achieve and maintain a level of exercise needed to obtain these benefits. It is therefore clinically important to find an effective, safe and inexpensive method of increasing HDL-c levels in people with chronic tetraplegia. This study will investigate the effects of omega-3 fatty acid supplementation on the lipid profile of people with tetraplegia. The investigators hypothesize that 5 months of daily consumption of high doses of omega-3 fatty acids will increase plasma levels of HDL-c in those with tetraplegia, leading to decreased risk of cardiovascular health issues.

NCT ID: NCT01245738 Completed - Clinical trials for Hypercholesterolemia

Effect of Statins on Lipid Levels Following the First Acute Coronary Event (MK-0000-204)

REMAINS
Start date: August 2010
Phase: N/A
Study type: Observational

The current study is proposed to investigate the pattern of dyslipidemia and of lipid treatment practices in patients in India experiencing their first acute cardiovascular event and the extent of residual dyslipidemia after 12 weeks of treatment with statins. Dyslipidemia definitions are per the National Cholesterol Education Program - Adult Treatment Panel III (NCEP-ATP III).